transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2024-11-1-28-44AQPQQRtransmed-834Research ArticleНАНОТЕХНОЛОГИИNANOTECHNOLOGYПрототипы «ловушек» вируса SARS-CoV-2 на основе энтеросорбентовPrototypes of SARS-CoV-2 virus “traps” based on enterosorbentsШульмейстерГ. А.ShulmeysterG. A.

Галина Анатольевна Шульмейстер, младший научный сотрудник

НИЛ нанотехнологий

Санкт-Петербург

Galina A. Shulmeyster, Junior Research Assistant

Research Laboratory of Nanotechnologies

Saint Petersburg

ЧебуркинЮ. В.CheburkinYu. V.

Юрий Владимирович Чебуркин, к. м. н., заведующий НИЛ, старший научный сотрудник

НИЛ инфекционных патогенов и биомолекулярных наноструктур; НИО микроциркуляции и метаболизма миокарда

Санкт-Петербург

Yuri V. Cheburkin, MD, PhD, Head of Laboratory, SeniorResearch Scientist

Research Laboratory of Infectious Pathogens and Biomolecular Nanostructures; Department Microcirculation and Myocardial Metabolism

Saint Petersburg

ЧекменеваЮ. Д.ChekmenevaYu. D.

Юлия Дмитриевна Чекменева, студент

Санкт-Петербург

Yulia D. Chekmeneva, Student

Saint Petersburg

ЕдемскаяЕ. В.EdemskayaE. V.

Елена Владимировна Едемская, студент

197022; ул. Профессора Попова, д. 5, лит. Ф; Санкт-Петербург

Elena V. Edemskaya, Student

197022; Professor Popov str., 5-F; Saint Petersburg

evedemskaya@stud.etu.ruБондаренкоА. Б.BondarenkoA. B.

Андрей Борисович Бондаренко, младший научный сотрудник, старший преподаватель

НИЛ инфекционных патогенов и биомолекулярных наноструктур; кафедра медицинской биологии

Санкт-Петербург

Andrey B. Bondarenko, junior research assistant

Research Laboratory of Infectious Pathogens andBiomolecular Nanostructures

Saint Petersburg

ПостновВ. Н.PostnovV. N.

Виктор Николаевич Постнов, к. х. н., доцент, старший научный сотрудник

Институт химии; кафедра химии твердого тела; НИЛ нанотехнологий

Санкт-Петербург

Viktor N. Postnov, MD, PhD, Assistant Professor, Senior Researcher

Institute of Chemistry; Research Laboratory of Nanotechnologies

Saint Petersburg

КоролевД. В.KorolevD. V.

Дмитрий Владимирович Королев, д. х. н., заведующий НИЛ, научный сотрудник

НИЛ нанотехнологий

Санкт-Петербург

Dmitry V. Korolev, PhD, Head of the Laboratory

Research Laboratory of Nanotechnologies

Saint Petersburg

dimon@cardioprotect.spb.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Санкт-Петербургский государственный электротехнический университет «ЛЭТИ» имени В. И. Ульянова (Ленина)»РоссияSaint Petersburg Electrotechnical University “LETI”Russian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research Centre; Saint Petersburg State Pediatric Medical UniversityRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»РоссияAlmazov National Medical Research Centre; Saint Petersburg State UniversityRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research Centre; Academician I. P. Pavlov First Saint Petersburg State Medical UniversityRussian Federation2024150420241112844Copyright © Шульмейстер Г.А., Чебуркин Ю.В., Чекменева Ю.Д., Едемская Е.В., Бондаренко А.Б., Постнов В.Н., Королев Д.В., 20242024Шульмейстер Г.А., Чебуркин Ю.В., Чекменева Ю.Д., Едемская Е.В., Бондаренко А.Б., Постнов В.Н., Королев Д.В.Shulmeyster G.A., Cheburkin Y.V., Chekmeneva Y.D., Edemskaya E.V., Bondarenko A.B., Postnov V.N., Korolev D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/834   Актуальность

   Актуальность. Несмотря на продолжающиеся мутации вируса SARS-CoV-2, возбудителя заболевания COVID-19, его механизм проникновения в клетку остается неизменным, что можно использовать для создания «ловушек» вируса. Лекарственные препараты с внутривенным введением усугубляют симптомы заболевания. Альтернативными средствами борьбы с вирусом могут стать энтеросорбенты, синтезированные на наноразмерных носителях, перехватывающие SARS-CoV-2 непосредственно в месте его внедрения в организм, а именно в органах желудочно-кишечного тракта.

   Цель

   Цель. Изучение и отработка методов синтеза различных видов спейсера на поверхности наночастиц аэросила, иммобилизация модельного белка с возможностью использования соединений в качестве энтеросорбента вируса SARS-CoV-2.

   Материалы и методы

   Материалы и методы. В качестве наночастиц-носителей использовался аэросил марки А-200. Химический состав полученных соединений изучался с помощью ИК-Фурье спектроскопии. Спектры поглощения образцов исследовались спектрофотометрически. Размеры нанообъектов определялись методом динамического рассеяния света. Общее содержание аминогрупп определялось титрометрическим способом и по емкости флуоресцентного красителя — индоцианина зеленого, количество меркаптогрупп определялось аргентометрией и с помощью метода Кункеля, Баркли и Горина. Проведено качественное и количественное определение хемосорбции белка на синтезированных частицах.

   Полученные результаты

   Полученные результаты. Разработаны прототипы энтеросорбентов вируса SARS-CoV-2 на частицах аэросила. Синтезированы амино-, меркапто- и тозильный спейсеры, способные связываться с разными функциональными группами белков, изучены физико-химические свойства модифицированных наночастиц. Эффективность спейсеров проверена на модельном белке — альбумине.

   Заключение

   Заключение. Дальнейшие исследования могут быть направлены на разработку перорального препарата, уменьшающего вирусную нагрузку SARS-CoV-2 на органы желудочно-кишечного тракта.

   Background

   Background. Despite the ongoing mutations of the SARS-CoV-2 virus, the causative agent of the COVID-19 disease, its mechanism of entry into the cell remains unchanged, which can be used to create virus “traps”. Intravenous medications aggravate the symptoms of the disease. An alternative means of combating the virus could be enterosorbents synthesized on nanosized carriers that intercept SARS-CoV-2 directly at the site of its introduction into the body, namely in the gastrointestinal tract.

   Objective

   Objective. To study and refine the methods of synthesis of different spacer types on the surface of aerosil nanoparticles, immobilization of model protein with the possibility of using the compounds as enterosorbents of SARS-CoV-2 virus.

   Design and method

   Design and method. Aerosil A-200 grade was used as carrier nanoparticles. The chemical composition of the obtained compounds was studied by FTIR spectroscopy. The absorption spectra of the samples were studied using a spectrophotometer. The dimensions of nano-objects were determined by dynamic light scattering. Qualitative and quantitative determination of protein chemisorption on the synthesized particles was carried out.

   Results

   Results. Prototypes of SARS-CoV-2 enterosorbents on aerosil particles were developed. The efficacy of the spacers was tested on the model protein, albumin.

   Conclusion

   Conclusion. Further research may be directed to the development of an oral drug that reduces the viral load of SARS-CoV-2.

белки-«ловушки»иммобилизация белкасинтез спейсераэнтеросорбентSARS- CoV-2enterosorbentsprotein immobilizationSARS-CoV-2spacer synthesistrap proteinsРабота выполнена в рамках государственного задания Минздрава РФ № 121031100284–7The work is performed within the State task of the Ministry of Health of the Russian Federation № 121031100284–7ReferencesAndersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat. Med. 2020; 26: 450–452. DOI: 10.1038/s41591-020-0820-9.Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat. Med. 2020; 26: 450–452. DOI: 10.1038/s41591-020-0820-9.Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020; 17: 259–260. DOI: 10.1038/s41569-020-0360-5.Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020; 17: 259–260. DOI: 10.1038/s41569-020-0360-5.Raj VS, Mou H, Saskia L, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013; 495: 251–254. DOI: 10.1038/nature12005.Raj VS, Mou H, Saskia L, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013; 495: 251–254. DOI: 10.1038/nature12005.Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020; 176: 104742. DOI: 10.1016/j.antiviral.2020.104742.Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020; 176: 104742. DOI: 10.1016/j.antiviral.2020.104742.Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance. 2020; 3(9). DOI: 10.26508/lsa.202000786.Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance. 2020; 3(9). DOI: 10.26508/lsa.202000786.Serfozo P, Wysocki J, Gulua G, et al. Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is pop (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension. 2020; 75: 173–182. DOI: 10.1161/HYPERTENSIONAHA.119.14071.Serfozo P, Wysocki J, Gulua G, et al. Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is pop (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension. 2020; 75: 173–182. DOI: 10.1161/HYPERTENSIONAHA.119.14071.Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004; 203: 631–637. DOI: 10.1002/path.1570.Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004; 203: 631–637. DOI: 10.1002/path.1570.Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009; 7: 226–236. DOI: 10.1038/nrmicro2090.Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009; 7: 226–236. DOI: 10.1038/nrmicro2090.Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020; 395: 565–574. DOI: 10.1016/S0140-6736(20)30251-8.Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020; 395: 565–574. DOI: 10.1016/S0140-6736(20)30251-8.Menachery VD, Yount BL, Debbink K, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015; 21: 1508–1513. DOI: 10.1038/nm.3985.Menachery VD, Yount BL, Debbink K, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015; 21: 1508–1513. DOI: 10.1038/nm.3985.Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: Prevention of angiotensin II-dependent hypertension. Hypertension. 2010; 55: 90–98. DOI: 10.1161/HYPERTENSIONAHA.109.138420.Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: Prevention of angiotensin II-dependent hypertension. Hypertension. 2010; 55: 90–98. DOI: 10.1161/HYPERTENSIONAHA.109.138420.Hofmann H, Geier M, Marzi A. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem. Biophys. Res. Commun. 2004; 319(4): 1216–1221. DOI: 10.1016/j.bbrc.2004.05.114.Hofmann H, Geier M, Marzi A. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem. Biophys. Res. Commun. 2004; 319(4): 1216–1221. DOI: 10.1016/j.bbrc.2004.05.114.Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin. Sci. (Lond.). 2020; 134(5): 543–545. DOI: 10.1042/CS20200163.Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin. Sci. (Lond.). 2020; 134(5): 543–545. DOI: 10.1042/CS20200163.Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426: 450–454. DOI: 10.1038/nature02145.Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426: 450–454. DOI: 10.1038/nature02145.Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003; 348: 1953–1966. DOI: 10.1056/NEJMoa030781.Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003; 348: 1953–1966. DOI: 10.1056/NEJMoa030781.Lei C, Qian K, Li T, et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat. Commun. 2020; 11(1): 2070. DOI: 10.1038/s41467-020-16048-4.Lei C, Qian K, Li T, et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat. Commun. 2020; 11(1): 2070. DOI: 10.1038/s41467-020-16048-4.Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483): 1260–1263. DOI: 10.1126/science.abb2507.Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483): 1260–1263. DOI: 10.1126/science.abb2507.Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 2020; 94(7). DOI: 10.1128/JVI.00127-20.Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 2020; 94(7). DOI: 10.1128/JVI.00127-20.Vankadari N, Wilce JA. Emerging WuHan COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg. Microbes. Infect. 2020; 9(1): 601–604. DOI: 10.1080/22221751.2020.1739565.Vankadari N, Wilce JA. Emerging WuHan COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg. Microbes. Infect. 2020; 9(1): 601–604. DOI: 10.1080/22221751.2020.1739565.Watanabe Y, Bowden TA, Wilson IA, et al. Exploitation of glycosylation in enveloped virus pathobiology. Biochim. Biophys. Acta. Gen. Subj. 2019; 1863(10): 1480–1497. DOI: 10.1016/j.bbagen.2019.05.012.Watanabe Y, Bowden TA, Wilson IA, et al. Exploitation of glycosylation in enveloped virus pathobiology. Biochim. Biophys. Acta. Gen. Subj. 2019; 1863(10): 1480–1497. DOI: 10.1016/j.bbagen.2019.05.012.Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol. Rev. 1998; 161: 55–70. DOI: 10.1111/j.1600-065x.1998.tb01571.x.Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol. Rev. 1998; 161: 55–70. DOI: 10.1111/j.1600-065x.1998.tb01571.x.Wang Q, Qi J, Yuan Y, et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host & Microbe. 2014; 16(3): 328–337. DOI: 10.1016/j.chom.2014.08.009.Wang Q, Qi J, Yuan Y, et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host & Microbe. 2014; 16(3): 328–337. DOI: 10.1016/j.chom.2014.08.009.Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci. 2020; 63(3): 457–460. DOI: 10.1007/s11427-020-1637-5.Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci. 2020; 63(3): 457–460. DOI: 10.1007/s11427-020-1637-5.Gohrbandt S, Veits J, Breithaupt A, et al. H9 avian influenza reassortant with engineered polybasic cleavage site displays a highly pathogenic phenotype in chicken. J. Gen. Virol. 2011; 92: 1843–1853. DOI: 10.1099/vir.0.031591-0.Gohrbandt S, Veits J, Breithaupt A, et al. H9 avian influenza reassortant with engineered polybasic cleavage site displays a highly pathogenic phenotype in chicken. J. Gen. Virol. 2011; 92: 1843–1853. DOI: 10.1099/vir.0.031591-0.Rabaan AA, Al-Ahmed Shamsah H, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview Infez Med. 2020; 28(2): 174–184.Rabaan AA, Al-Ahmed Shamsah H, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview Infez Med. 2020; 28(2): 174–184.Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2): 281–292. DOI: 10.1016/j.cell.2020.02.058.Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2): 281–292. DOI: 10.1016/j.cell.2020.02.058.Nao N, Yamagishi J, Miyamoto H, et al. Genetic predisposition to acquire a polybasic cleavage site for highly pathogenic avian influenza virus hemagglutinin. MBio. 2017; 8(1). DOI: 10.1128/mBio.02298-16.Nao N, Yamagishi J, Miyamoto H, et al. Genetic predisposition to acquire a polybasic cleavage site for highly pathogenic avian influenza virus hemagglutinin. MBio. 2017; 8(1). DOI: 10.1128/mBio.02298-16.Jaimes JA, Millet JK, Whittaker GR. Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. IScience. 2020; 23(6): 101212. DOI: 10.1016/j.isci.2020.101212.Jaimes JA, Millet JK, Whittaker GR. Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. IScience. 2020; 23(6): 101212. DOI: 10.1016/j.isci.2020.101212.Follis KE, York J, Nunberg JH. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell–cell fusion but does not affect virion entry. Virology. 2006; 350(2): 358–69. DOI: 10.1016/j.virol.2006.02.003.Follis KE, York J, Nunberg JH. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell–cell fusion but does not affect virion entry. Virology. 2006; 350(2): 358–69. DOI: 10.1016/j.virol.2006.02.003.Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020; 181(4): 905–913. DOI: 10.1016/j.cell.2020.04.004.Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020; 181(4): 905–913. DOI: 10.1016/j.cell.2020.04.004.Чебуркин Ю.В., Сонин Д.Л., Полозов А.С. и др. Роль мембранной и циркулирующей форм ACE 2 в развитии различных патологических процессов на фоне COVID-19. Артериальная гипертензия. 2021; 27(6):608–616. DOI:10.18705/1607-419X-2021-27-6-608-616Cheburkin YV, Sonin DL, Polozov AS, et al. The role of membrane and circulating forms of ACE 2 in pathological processes in COVID19 infection. Arterial’naya Gipertenziya = Arterial Hypertension. 2021; 27(6):608–616. DOI:10.18705/1607-419X-2021-27-6-608-616 In RussianZhang G, Pomplun S, Loftis A, et al. Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 Spike RBD. BioRxiv. 2020. [Preprint]. doi: 10.1101/2020.03.19.999318.Zhang G, Pomplun S, Loftis A, et al. Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 Spike RBD. BioRxiv. 2020. [Preprint]. doi: 10.1101/2020.03.19.999318.Baum A, Fulton B, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020; 369(6506): 1014–1018. DOI: 10.1126/science.abd0831.Baum A, Fulton B, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020; 369(6506): 1014–1018. DOI: 10.1126/science.abd0831.Clinical Trial NCT04335136. Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients with COVID-19 (APN01-COVID-19). https://clinicaltrials.gov/ct2/show/NCT04335136.Clinical Trial NCT04335136. Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients with COVID-19 (APN01-COVID-19). https://clinicaltrials.gov/ct2/show/NCT04335136.Zorin VN, Naumisheva EB, Postnov VN, et al. Magnetic nanoparticles for medical application with a coating deposited with various methods. J. Phys. Conf. Series. IOP Publishing, 2018; 1124(3). DOI: 10.1088/1742-6596/1124/3/031009.Zorin VN, Naumisheva EB, Postnov VN, et al. Magnetic nanoparticles for medical application with a coating deposited with various methods. J. Phys. Conf. Series. IOP Publishing, 2018; 1124(3). DOI: 10.1088/1742-6596/1124/3/031009.Ивановская А.М., Воронин А.В., Серякова А.Н. Количественный анализ лекарственных средств органической природы. Самара: Инсома-пресс, 2018. C. 88Ivanovskaya AM, Voronin AV, Seryakova AN. Quantitative analysis of drugs of organic nature. Samara: Insoma-press, 2018. P. 88. In Russian.Мурашова В.И., Тананаева А.Н., Ховякова Р.Ф. Качественный химический дробный анализ. М.: Химия, 1976. С. 279Murashova VI, Tananaeva AN, Khovyakova RF. Qualitative chemical fractional analysis. M.: Khimiya, 1976. Р. 279. In Russian.Сиггиа С. Инструментальные методы анализа функциональных групп органических соединений. М.: Мир, 1974. С. 464Siggia S. Instrumental methods for the analysis of functional groups of organic compounds. M.: Mir, 1974. P. 464. In Russian.Mahler GR, Cordes JG. Fundamentals of biological chemistry. Transl. from Eng. M.: Mir, 1970. P. 568. In Russian [Малер Г.Р., Кордес Ю.Г. Основы биологической химии. Пер. с англ. М.: Мир, 1970. С. 568].Mahler GR, Cordes JG. Fundamentals of biological chemistry. Transl. from Eng. M.: Mir, 1970. P. 568. In Russian [Малер Г.Р., Кордес Ю.Г. Основы биологической химии. Пер. с англ. М.: Мир, 1970. С. 568].Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromocresol green. Clin. Chim. Acta. 1971; 31: 87–96. DOI: 10.1016/s0009-8981(96)06447-9.Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromocresol green. Clin. Chim. Acta. 1971; 31: 87–96. DOI: 10.1016/s0009-8981(96)06447-9.Narang AS, Varia S. Role of tumor vascular architecture in drug delivery. Adv. Drug. Deliv. Rev. 2011; 63(8): 640–658. DOI: 10.1016/j.addr.2011.04.002.Narang AS, Varia S. Role of tumor vascular architecture in drug delivery. Adv. Drug. Deliv. Rev. 2011; 63(8): 640–658. DOI: 10.1016/j.addr.2011.04.002.Kozlowski LP. Proteome-pI: proteome isoelectric point database. Nuc. Acids Res. 2017; 45(D1): D1112–D1116. DOI: 10.1093/nar/gkw978.Kozlowski LP. Proteome-pI: proteome isoelectric point database. Nuc. Acids Res. 2017; 45(D1): D1112–D1116. DOI: 10.1093/nar/gkw978.Gareev KG, Babikova KY, Postnov VN, et al. Fluorescence imaging of the nanoparticles modified with indocyanine green. J. Phys. 2017: Conf. Series 917 042008. DOI: 10.1088/1742-6596/917/4/042008.Gareev KG, Babikova KY, Postnov VN, et al. Fluorescence imaging of the nanoparticles modified with indocyanine green. J. Phys. 2017: Conf. Series 917 042008. DOI: 10.1088/1742-6596/917/4/042008.Korolev DV, Evreinova NV, Zakharova EV, et al. Phosphocreatine immobilization of the surface of silicaand magnetite nanoparticles for targeted drug delivery. Russian Chemical Bulletin. 2019; 68(5): 1096–1101. DOI: 10.1007/s11172-019-2525-0.Korolev DV, Evreinova NV, Zakharova EV, et al. Phosphocreatine immobilization of the surface of silicaand magnetite nanoparticles for targeted drug delivery. Russian Chemical Bulletin. 2019; 68(5): 1096–1101. DOI: 10.1007/s11172-019-2525-0.Korolev DV, Postnov VN, Evreinovaa NV, et al. Synthesis of Magnetic Nanoparticles with Radiopaque Marker. Rus. J. Gen. Chem.2018; 88(12): 2698–2701. DOI: 10.1134/S1070363218120381.Korolev DV, Postnov VN, Evreinovaa NV, et al. Synthesis of Magnetic Nanoparticles with Radiopaque Marker. Rus. J. Gen. Chem.2018; 88(12): 2698–2701. DOI: 10.1134/S1070363218120381.Han H, Wang Q, Liu X, et al. Polymeric ionic liquid modified organic-silica hybrid monolithic column for capillary electrochromatography/ J. Chromatogr. A. 2012; 1246: 9–14. DOI: 10.1016/j.chroma.2011.12.029.Han H, Wang Q, Liu X, et al. Polymeric ionic liquid modified organic-silica hybrid monolithic column for capillary electrochromatography/ J. Chromatogr. A. 2012; 1246: 9–14. DOI: 10.1016/j.chroma.2011.12.029.Lee BY, Li Z, Clemens DL, et al. Redox-triggered release of moxifloxacin from mesoporous silica nanoparticles functionalized with disulfide snap-tops enhances efficacy against pneumonic tularemia in mice. Small. 2016; 12(27): 3690–3702. DOI: 10.1002/smll.201600892.Lee BY, Li Z, Clemens DL, et al. Redox-triggered release of moxifloxacin from mesoporous silica nanoparticles functionalized with disulfide snap-tops enhances efficacy against pneumonic tularemia in mice. Small. 2016; 12(27): 3690–3702. DOI: 10.1002/smll.201600892.Klesiewicz K, Karczewska E, Budak A, et al. Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone. The Journal of antibiotics. 2016; 69(11): 825–834. DOI: 10.1038/ja.2016.36.Klesiewicz K, Karczewska E, Budak A, et al. Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone. The Journal of antibiotics. 2016; 69(11): 825–834. DOI: 10.1038/ja.2016.36.Sahudin MA, Su’ait MS, Tan LL, et al. Schiff base complex/TiO2 chemosensor for visual detection of food freshness level. Spectrochimica Acta Part A: Mol. Biomolec. Spectr.2021; 248: 119129. DOI: 10.1016/j.saa.2020.119129.Sahudin MA, Su’ait MS, Tan LL, et al. Schiff base complex/TiO2 chemosensor for visual detection of food freshness level. Spectrochimica Acta Part A: Mol. Biomolec. Spectr.2021; 248: 119129. DOI: 10.1016/j.saa.2020.119129.Kim J, Cho J, Seidler PM, et al. Investigations of chemical modifications of amino-terminated organic films on silicon substrates and controlled protein immobilization. Langmuir. 2010; 26(4): 2599–608. DOI: 10.1021/la904027p.Kim J, Cho J, Seidler PM, et al. Investigations of chemical modifications of amino-terminated organic films on silicon substrates and controlled protein immobilization. Langmuir. 2010; 26(4): 2599–608. DOI: 10.1021/la904027p.Li H, Pan J, Gao C, et al. Mercapto-functionalized porous organosilica monoliths loaded with gold nanoparticles for catalytic application. Molecules. 2019; 24(23): 4366. DOI: 10.3390/molecules24234366.Li H, Pan J, Gao C, et al. Mercapto-functionalized porous organosilica monoliths loaded with gold nanoparticles for catalytic application. Molecules. 2019; 24(23): 4366. DOI: 10.3390/molecules24234366.Senkevich JJ, Mitchell CJ, Yang GR, et al. Surface chemistry of mercaptan and growth of pyridine short-chain alkoxy silane molecular layers. Langmuir. 2002; 18(5): 1587–1594. DOI: 10.1021/la010970f.Senkevich JJ, Mitchell CJ, Yang GR, et al. Surface chemistry of mercaptan and growth of pyridine short-chain alkoxy silane molecular layers. Langmuir. 2002; 18(5): 1587–1594. DOI: 10.1021/la010970f.Kocyigit A. Properties of silicon–ZnO hybrid nanoparticles. In: Silicon-Based Hybrid Nanoparticles: Fundamentals, Properties, and Applications. 2022: 65–88. DOI: 10.1016/B978-0-12-824007-6.00001-0.Kocyigit A. Properties of silicon–ZnO hybrid nanoparticles. In: Silicon-Based Hybrid Nanoparticles: Fundamentals, Properties, and Applications. 2022: 65–88. DOI: 10.1016/B978-0-12-824007-6.00001-0.SpectraBase p-Toluenesulfonyl chloride 630–430 cm-1 wave number. https://spectrabase.com/spectrum/LNTt3QsvohK.SpectraBase p-Toluenesulfonyl chloride 630–430 cm-1 wave number. https://spectrabase.com/spectrum/LNTt3QsvohK.SpectraBase p-Toluenesulfonyl chloride 1260–1080 cm-1 wave number. https://spectrabase.com/spectrum/AODKWz6bA9PSpectraBase p-Toluenesulfonyl chloride 1260–1080 cm-1 wave number. https://spectrabase.com/spectrum/AODKWz6bA9PBrunauer S, Deming LS, Deming WE, et al. On a theory of the van der Waals adsorption of gases. J.Americ. Chem. Soc. 1940; 62: 1723–1732. DOI: 10.1021/ja01864a025.Brunauer S, Deming LS, Deming WE, et al. On a theory of the van der Waals adsorption of gases. J.Americ. Chem. Soc. 1940; 62: 1723–1732. DOI: 10.1021/ja01864a025.Yu M, Wu J, Shi J, Farokhzad OC. Nanotechnology for protein delivery: Overview and perspectives. J Control Release. 2016; 240:24–37. DOI: 10.1016/j.jconrel.2015.10.012.Yu M, Wu J, Shi J, Farokhzad OC. Nanotechnology for protein delivery: Overview and perspectives. J Control Release. 2016; 240:24–37. DOI: 10.1016/j.jconrel.2015.10.012.Chen M, Rosenberg J, Cai X, et al. Nanotraps for the containment and clearance of SARS-CoV-2. Matter. 2021; 4(6):2059–2082. DOI: 10.1016/j.matt.2021.04.005.Chen M, Rosenberg J, Cai X, et al. Nanotraps for the containment and clearance of SARS-CoV-2. Matter. 2021; 4(6):2059–2082. DOI: 10.1016/j.matt.2021.04.005.

The authors declare that there are no conflicts of interest present.